These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28546502)

  • 61. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.
    Venkatesha SH; Dudics S; Acharya B; Moudgil KD
    Int J Mol Sci; 2014 Dec; 16(1):887-906. PubMed ID: 25561237
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The TNF superfamily in 2009: new pathways, new indications, and new drugs.
    Tansey MG; Szymkowski DE
    Drug Discov Today; 2009 Dec; 14(23-24):1082-8. PubMed ID: 19837186
    [TBL] [Abstract][Full Text] [Related]  

  • 63. VHH-Based Bispecific Antibodies Targeting Cytokine Production.
    Nosenko MA; Atretkhany KN; Mokhonov VV; Efimov GA; Kruglov AA; Tillib SV; Drutskaya MS; Nedospasov SA
    Front Immunol; 2017; 8():1073. PubMed ID: 28919896
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions.
    Bombardieri M; McInnes IB; Pitzalis C
    Expert Opin Biol Ther; 2007 Jan; 7(1):31-40. PubMed ID: 17150017
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Proinflammatory and Immunoregulatory Functions of Interleukin 6 as Identified by Reverse Genetics].
    Drutskaya MS; Gogoleva VS; Atretkhany KN; Gubernatorova EO; Zvartsev RV; Nosenko MA; Nedospasov SA
    Mol Biol (Mosk); 2018; 52(6):963-974. PubMed ID: 30633239
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Autoimmune-like syndromes during TNF blockade: does infection have a role?
    Prinz JC
    Nat Rev Rheumatol; 2011 Mar; 7(7):429-34. PubMed ID: 21448162
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Modulation of bioavailability of proinflammatory cytokines produced by myeloid cells.
    Nosenko MA; Atretkhany KN; Mokhonov VV; Vasilenko EA; Kruglov AA; Tillib SV; Drutskaya MS; Nedospasov SA
    Semin Arthritis Rheum; 2019 Dec; 49(3S):S39-S42. PubMed ID: 31779851
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Editorial: Switching to biological agents in autoimmune and autoinflammatory disorders: current targets and therapy.
    Gasparyan AY
    Curr Med Chem; 2015; 22(16):1890-1. PubMed ID: 25693591
    [No Abstract]   [Full Text] [Related]  

  • 69. Septic Shock Had the Highest Concentrations of Cytokines, Yet Patients With Autoimmune Diseases have Very Low Blood Levels of Cytokines, But Dramatically Respond to Cytokine Inhibitors: How Should We Really Look at This?
    Honore PM; Redant S; Preseau T; Kaefer K; Barreto Gutierrez L; Attou R; Gallerani A; De Bels D
    Shock; 2021 Nov; 56(5):873. PubMed ID: 33978608
    [No Abstract]   [Full Text] [Related]  

  • 70. Is anti-TNF therapy safer than previously thought?
    Dixon W; Felson DT
    JAMA; 2011 Dec; 306(21):2380-1. PubMed ID: 22056396
    [No Abstract]   [Full Text] [Related]  

  • 71. [Molecular-Targeted Therapy and Autoimmune Disease].
    Takemura M; Wada T
    Rinsho Byori; 2016 Jun; 64(6):699-700. PubMed ID: 30695328
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dynamic manifestation of autoimmune diseases in skin-cytokine hubs and paradoxic reactions.
    Shao S; Billi AC; Gudjonsson JE
    J Allergy Clin Immunol; 2022 Jan; 149(1):45-47. PubMed ID: 34838585
    [No Abstract]   [Full Text] [Related]  

  • 73. Optimization of current and future therapy for autoimmune diseases.
    Steinman L; Merrill JT; McInnes IB; Peakman M
    Nat Med; 2012 Jan; 18(1):59-65. PubMed ID: 22227674
    [No Abstract]   [Full Text] [Related]  

  • 74. Care needs to be taken when reviewing malignancy data reported from observational studies: comment on the article by Onel and Onel.
    Mariette X; Reynolds A; Emery P
    Arthritis Care Res (Hoboken); 2011 Mar; 63(3):461-3; author reply 463-4. PubMed ID: 20981807
    [No Abstract]   [Full Text] [Related]  

  • 75. Letter to the editor: Re: Periodontal condition of patients with autoimmune diseases and the effect of anti-tumor necrosis factor-α therapy.
    Chava VK; Samudrala P
    J Periodontol; 2014 Mar; 85(3):372. PubMed ID: 24588525
    [No Abstract]   [Full Text] [Related]  

  • 76. TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond.
    Siegmund D; Wajant H
    Nat Rev Rheumatol; 2023 Sep; 19(9):576-591. PubMed ID: 37542139
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Study on the Multitarget Mechanism of Sanmiao Pill on Gouty Arthritis Based on Network Pharmacology.
    Qian H; Jin Q; Liu Y; Wang N; Chu Y; Liu B; Liu Y; Jiang W; Song Y
    Evid Based Complement Alternat Med; 2020; 2020():9873739. PubMed ID: 32831884
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review.
    Davignon JL; Rauwel B; Degboé Y; Constantin A; Boyer JF; Kruglov A; Cantagrel A
    Arthritis Res Ther; 2018 Oct; 20(1):229. PubMed ID: 30314507
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Platelet-Derived Microparticles: A New Index of Monitoring Platelet Activation and Inflammation in Kawasaki Disease.
    Jin J; Wang J; Lu Y; Fan Z; Huang N; Ma L; Yu H
    Indian J Pediatr; 2019 Mar; 86(3):250-255. PubMed ID: 30159809
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A New Venue of TNF Targeting.
    Steeland S; Libert C; Vandenbroucke RE
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29751683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.